Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. - Wikidata - awgldk - TriplyDB

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.

http://www.wikidata.org/entity/Q34059726

about

Current status of transarterial radioembolization Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements.Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases.Multidisciplinary approach of colorectal cancer liver metastases.Radioembolization of hepatic tumors Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer Colorectal hepatic metastasis: Evolving therapies.Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres.Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer Radioembolization for primary and metastatic liver cancer.Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.Curative strategies for liver metastases from colorectal cancer: a review Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience.Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.Semi-Quantitative Analysis of Post-Transarterial Radioembolization (90)Y Microsphere Positron Emission Tomography Combined with Computed Tomography (PET/CT) Images in Advanced Liver Malignancy: Comparison With (99m)Tc Macroaggregated Albumin (MAA) S Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres Administered activity and outcomes of glass versus resin (90)Y microsphere radioembolization in patients with colorectal liver metastases.Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).Selective Interarterial Radiation Therapy (SIRT) in Colorectal Liver Metastases: How Do We Monitor Response?Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes.Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.Pretreatment tumor volume as a prognostic factor in metastatic colorectal cancer treated with selective internal radiation to the liver using yttrium-90 resin microspheres.Clinical Interventional Oncology Symposium And Integrative Healthcare Symposium Arterial therapies of colorectal cancer metastases to the liver.Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer.Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part II: multidisciplinary management.Exploiting microspheres as a therapeutic proficient doer for colon delivery: a review.A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.Intra-arterial therapies for metastatic colorectal cancer.The effect of intra-arterial angiotensin II on the hepatic tumor to non-tumor blood flow ratio for radioembolization: a systematic review.Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature.Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review.Advances in understanding of colorectal liver metastasis and implications for the clinic.Yttrium-90 radioembolization of hepatic metastases from colorectal cancer.Liver resection for metastatic disease after y90 radioembolization: a case series with long-term follow-up.Liver-directed therapies in metastatic colorectal cancer.

P2860

Q26744307-9377187A-57E4-4867-9FEF-2D23A46AA4C5 Q30415022-F8F4B8B6-1BF4-4D46-AF76-B5AC1E66969D Q33594891-1191F706-2A05-43C4-81E7-60F04C92B711 Q33618754-D4465029-5425-4234-B620-2120241EA0B5 Q33779859-F52B7269-F2BE-4D98-94A5-F5C00E145939 Q33820777-8E5C0D18-AA6B-48A8-8641-DF2C2FA2E1F4 Q33918145-B05D1DA1-E5D5-4DAF-A080-9B424AD242E6 Q34663557-4A83E816-F722-4512-BE82-9E532ED7B0FC Q35028984-D469DBAC-5D8E-47ED-9D5E-6098C1E381CC Q35230366-93F220BD-6922-4C27-8770-52CE7EA1B52F Q35564038-74252297-25CC-4869-B84B-E5622BE16A4F Q35691040-EFB836F4-D2F1-436C-A484-477E1D05F44A Q35776233-E22004B1-13A0-4854-B923-97002FD118A1 Q36080625-FA242580-04F3-4889-85FC-561B6D4699AD Q36083302-64A26822-6FDD-4D3E-8BD8-537648CC74F9 Q36352452-A4151D20-59C9-441B-A64D-D12D58DEDB30 Q36392298-6315323C-CE5A-4828-AD60-10172D7AD1F0 Q36605013-16F82118-0410-4432-916C-33B4879821C3 Q36656612-D95E6279-C44F-4DB5-8907-305994A87683 Q36697911-7C298B37-595B-4950-9E8A-51982E7CAB97 Q37131705-57E1D2E2-D62B-483E-B9F4-F7F71C57106F Q37308725-2E76E5FD-01A0-4503-A246-C611BBCA5EEC Q37316201-4E6DB42C-45BD-4C34-82AB-7FB68BF18969 Q37326857-53A51CAC-0E86-499D-BD31-0AD9FD4471E8 Q37525291-71191F9C-BE13-4872-A43D-9539D49AFEDD Q37525319-7C1A3EC3-0F7D-4F03-86DD-FC882A092AC7 Q37711918-0753916A-23D3-408F-94F7-67E1F66EBAED Q37890914-E7CB0DB2-669F-467E-9975-2E9E846BEBC6 Q37996428-AD4C9015-8D4E-4152-9E2F-37E24E4772E5 Q38001351-3E99E739-3498-4E07-9F4A-09C0A58B673B Q38073796-E0A10A8A-791E-4622-9365-70B60EEB838B Q38169587-FB1A62AA-6BA2-48EC-87E2-F5630D953B7F Q38179343-F90E8D17-B83D-41F6-BE41-5CD5EC8F9836 Q38182093-5A00A784-76AD-4955-8148-6EBB0C696115 Q38192781-BF7F169A-960A-4199-9EA7-756CCC8D333B Q38206730-F2EC2FFC-5290-42B1-A6A8-9488920C5EF7 Q38230654-B75B7527-73D9-47D1-A1EC-2CDA9D09BC3F Q38239688-49AFA914-CEBC-4DC1-9A34-36158A5F2812 Q38246198-617F4CBB-932C-471A-87F4-F86571015418 Q38256165-488D0561-40DB-4867-ADEB-44BD6A306A56

P2860

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.

http://www.wikidata.org/entity/Q34059726

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Multi-centre phase II clinical ...... y colorectal liver metastases.

@ast

Multi-centre phase II clinical ...... y colorectal liver metastases.

@en

Multi-centre phase II clinical ...... y colorectal liver metastases.

@nl

type

label

Multi-centre phase II clinical ...... y colorectal liver metastases.

@ast

Multi-centre phase II clinical ...... y colorectal liver metastases.

@en

Multi-centre phase II clinical ...... y colorectal liver metastases.

@nl

prefLabel

Multi-centre phase II clinical ...... y colorectal liver metastases.

@ast

Multi-centre phase II clinical ...... y colorectal liver metastases.

@en

Multi-centre phase II clinical ...... y colorectal liver metastases.

@nl

P1433

Q34059726-21871DF1-4670-4664-97AC-6F209E6256BC

P1476

Q34059726-E1048C8A-2112-4C87-A1DA-7ED8568FCA02

P2093

Q34059726-066C5122-9375-4725-8076-62F928F413EB

Q34059726-22560976-8CB5-43CE-8DFD-B71F035A9B32

Q34059726-35F8B82E-B659-41F3-AF3D-8BD187E6379D

Q34059726-40B1F0A9-CA80-4868-924D-C39CF5F64A53

Q34059726-4A074B6A-2F18-4D29-90E5-37C9AEF96A66

Q34059726-59C1CE69-B8EC-41C8-B243-F4D37DF3847B

Q34059726-6706C557-A728-4083-B8F9-14DE38B55BA2

Q34059726-887AAEFA-E1F3-4FF1-AF50-2E7FB4ABFB94

Q34059726-919B3A64-BA95-40EF-9540-33123B2CF67E

Q34059726-985EC9CF-20A8-405A-953F-E10F4E7A6C16

P2860

Q34059726-006941E2-16DD-4FB4-B456-CB98872561AC

Q34059726-01C14937-7FF2-4D0F-B558-89AC6E8EE455

Q34059726-0CD92441-9006-4F9C-9FEE-86C39592852C

Q34059726-15C48581-8BE0-4B05-8BAF-DF4EFAA12CF9

Q34059726-17AE3F6D-29C2-4A9B-8392-6CFC157F94F7

Q34059726-19E92D76-EA5F-4ED1-943A-FB59A91598CF

Q34059726-1D8D7D22-DAD2-4B6F-AB80-2BB4FF905DFA

Q34059726-22F8A0F4-FCD7-43D7-832F-28D5973BEFF6

Q34059726-2706D4B5-3A32-4CA2-B16D-9DB94D0BAB3E

Q34059726-27F740F2-26E6-4D3C-A6AD-7AD722443712

P2888

Q34059726-1C1A9880-7E0E-436F-8664-417C1B359189

P304

Q34059726-F360CD3A-13D7-4554-BE77-88FDB217669D

P31

Q34059726-AA0B627B-66C1-449A-A08D-11F175D202DD

P356

Q34059726-8B920A45-8A15-476F-9B59-19C051CC7486

P407

Q34059726-2CBA98D1-6A9D-4932-8BAE-59F3E1FA4389

P433

Q34059726-B9B5C9EF-608B-4B56-9741-64D8AF3B0ADE

P478

Q34059726-2AA9DC20-B254-4DBF-A0D5-118241971797

P50

Q34059726-366E4291-5BF6-47DE-AD25-8039E59F58C8

Q34059726-4ED8A179-03A3-413D-B62D-6D39BBA0DA8D

Q34059726-5E30C79F-0C8E-45F5-AEAE-5EF7B751F718

P577

Q34059726-EE9E91E5-19A6-440E-B565-E5B6C362A47B

P5875

Q34059726-83C99852-B9F3-4ACD-AA63-851EF72952AD

P6179

Q34059726-1C12CE74-FC6E-4789-9D60-F53CF6E1D354

P698

Q34059726-EA4218C2-5ADB-459B-99F0-48C6A9A11E42

P921

Q34059726-0426F65B-52AE-4F17-ADAF-29D5369A588A

Q34059726-F657A339-05FE-4EA6-9889-6D70E3BD215C

Q34059726-F747611C-30DC-4005-9505-79EEFA94FD0F

P932

Q34059726-D2AE21CA-03D1-489B-9A1D-D3C77854AB22

P356

P1433

British Journal of Cancer

P1476

Multi-centre phase II clinical ...... y colorectal liver metastases.

@en

P2093

B Angelelli

http://www.w3.org/2001/XMLSchema#string

C L Maini

http://www.w3.org/2001/XMLSchema#string

D Gasperini

http://www.w3.org/2001/XMLSchema#string

E Giampalma

http://www.w3.org/2001/XMLSchema#string

F Fiore

http://www.w3.org/2001/XMLSchema#string

G Pizzi

http://www.w3.org/2001/XMLSchema#string

Italian Society of Locoregional Therapies in Oncology (SITILO)

http://www.w3.org/2001/XMLSchema#string

L Carpanese

http://www.w3.org/2001/XMLSchema#string

M G Diodoro

http://www.w3.org/2001/XMLSchema#string

M Perrone

http://www.w3.org/2001/XMLSchema#string

P2860

Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N99

Estimates of the cancer incidence and mortality in Europe in 2006.

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

Surgical strategies for colorectal liver metastases.

P2888

P304

324-331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605770

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Isabella Sperduti

Maurizio Cosimelli

P577

2010-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45185626

http://www.w3.org/2001/XMLSchema#string

P6179

1037075560

http://www.w3.org/2001/XMLSchema#string

P698

20628388

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2920024

http://www.w3.org/2001/XMLSchema#string